Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bekinda
- Development stage
- Unknown
- Lead developer
- RedHill Biopharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bekinda is a pharmaceutical drug being developed as an extended-release oral formulation of ondansetron, a selective serotonin 5-HT3 receptor antagonist. Its primary mechanism of action is the inhibition of serotonin (5-HT3) receptors, which are involved in triggering nausea and vomiting. Bekinda is primarily intended for the treatment of acute gastroenteritis and gastritis, as well as for irritable bowel syndrome with diarrhea (IBS-D). The drug aims to provide prolonged antiemetic effects compared to standard ondansetron formulations. It has been developed by RedHill Biopharma.
- Brand names
- BEKINDA
- Other names
- once-daily ondansetron
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)
Beyond the preview
Go deeper on Bekinda.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bekinda.